Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 73131 record(s)

Req # A-2019-001308

Adverse Reaction Report (AER) for Mesalamine, Mesalazin. Report numbers: E2B_02606624, E2B_02606638, E2B_0260664, E2B_02603286, E2B_02605383.

Organization: Health Canada

43 page(s)
January 2020

Req # A-2019-001310

Adverse Reaction Report (AER) for Adderall XR, and Mesalazine. Report numbers: E2B_02571534, E2B_02136664, E2B_02605385, E2B_ 02560159.

Organization: Health Canada

48 page(s)
January 2020

Req # A-2019-001453

Adverse Reaction Report (AER). Report numbers: E2B_02688836, E2B_02691744, E2B_02691243, E2B_02693254.

Organization: Health Canada

106 page(s)
January 2020

Req # A-2019-001346

Adverse Reaction Report (AER) for DEXILANT. Report numbers: 00726253, 000726460, 000726475, 000726674, 000726980, 000727460, E2B_02491366, E2B_02538249, E2B_02559280, E2B_02564898, E2B_02589953, E2B_02615425, E2B_02666199, E2B_02667689, E2B_02704921.

Organization: Health Canada

198 page(s)
January 2020

Req # A-2019-001347

Adverse Reaction Report (AER) for ENTYVIO. Report numbers: 725183, 725228, 726090, 728081, 728846, E2B_02440933, E2B_02449094, E2B_02450339, E2B_02467744, E2B_02476106, E2B_02506659, E2B_02510234, E2B_02514247, E2B_02516806, E2B_02523318,…

Organization: Health Canada

507 page(s)
January 2020

Req # A-2019-001416

Adverse Reaction Report (AER). Report numbers: 000668591, E2B_02060970, E2B_02031121, E2B_01054239, E2B_02068338, E2B_02068345 E2B_0l661674, E2B_02133750, E2B_02695701, E2B_02262257, E2B_02281763, E2B_01120025, E2B_02262720.

Organization: Health Canada

232 page(s)
January 2020

Req # A-2019-001439

Adverse Reaction Report (AER) for botulinum toxin type A. Report number: E2B_02666592.

Organization: Health Canada

18 page(s)
January 2020

Req # A-2019-001447

Adverse Reaction Report (AER). Report numbers: E2B_02682751, E2B_02689623, E2B_02697016, E2B_02697020.

Organization: Health Canada

59 page(s)
January 2020

Req # A-2019-001451

Adverse Reaction Report (AER). Report numbers: E2B_02677393, E2B_02680918, E2B_02680919, E2B_02686684.

Organization: Health Canada

49 page(s)
January 2020

Req # A-2019-001452

Adverse Reaction Report (AER). Report numbers: 000728695, E2B_02658460, E2B_02659856, E2B_02671562.

Organization: Health Canada

71 page(s)
January 2020
Date modified: